The Little Book of Valuation: How to Value a Company, Pick a Stock, and Profit

by Aswath Damodaran

Quick Summary

A concise yet comprehensive guide to company valuation by NYU professor Aswath Damodaran, covering intrinsic valuation (DCF), relative valuation (multiples), and their application across the full corporate lifecycle from young startups to distressed firms, including specialized chapters on banks, cyclical companies, and intangible-asset-heavy businesses.

Detailed Summary

Aswath Damodaran, widely regarded as the foremost academic authority on valuation, distills his extensive knowledge into an accessible format as part of the Little Book Big Profits series published by Wiley. The book is structured in three parts that progress from foundational tools through lifecycle-specific applications to special situations.

Part I, "Hit the Ground Running -- Valuation Basics," establishes the essential toolkit. "Value -- More Than a Number!" introduces the philosophy that valuation is both art and science, presenting two fundamental approaches (intrinsic and relative) and dispelling common misconceptions. Damodaran articulates several core truths: all valuations contain uncertainty, simpler models are often more robust than complex ones, and the market is usually right in the long run but can be wrong in the short run.

"Power Tools of the Trade" covers the three pillars of valuation mathematics: the time value of money (discounting and compounding), risk measurement and management (including the Capital Asset Pricing Model, multi-factor models, and implied cost of equity), and accounting fundamentals (reading financial statements, understanding accrual versus cash accounting, and identifying accounting distortions). "Yes, Virginia, Every Asset Has an Intrinsic Value" presents the discounted cash flow methodology in detail, distinguishing between valuing the entire business (enterprise value) versus just the equity, and demonstrating how different assumptions about cash flows, growth, and discount rates affect value. "It's All Relative!" covers comparable company analysis, standardized multiples (P/E, EV/EBITDA, P/B, P/S), the four keys to using multiples correctly (consistency, uniformity, comparability, and adjustment), and the important distinction between intrinsic and relative value.

Part II, "From Cradle to Grave -- Life Cycle and Valuation," addresses how valuation challenges change as companies mature. "Promise Aplenty" tackles the valuation of young, high-growth startups where revenues are minimal, losses are common, and the range of outcomes is enormous. "Growing Pains" covers maturing growth companies where the challenge shifts to forecasting the trajectory of growth deceleration and margin expansion. "Valuation Viagra" examines mature companies with the question of whether management changes can unlock hidden value through restructuring, spinoffs, or capital allocation improvements. "Doomsday" addresses distressed companies where the probability of survival must be explicitly incorporated into the valuation, including the option value of equity in a firm approaching bankruptcy.

Part III, "Breaking the Mold -- Special Situations," handles sectors and circumstances that require modified approaches. "Bank on It" addresses the unique challenges of valuing financial institutions where traditional free cash flow definitions break down because lending and borrowing are operating activities. "Roller-Coaster Investing" covers cyclical companies and commodity producers, including the real option argument for undeveloped reserves. "Invisible Value" examines companies whose primary assets are intangible -- technology firms, pharmaceutical companies, and brands -- where book value is meaningless and traditional metrics are misleading.

Throughout, Damodaran maintains his hallmark clarity, using real-world examples and practical frameworks rather than abstract theory. The book serves as both a standalone introduction for newcomers and a concentrated reference for experienced practitioners.